Category: Uncategorized

MEDICAL-DEVICE PRICE MANAGEMENT ACROSS THE SUPPLY CHAIN: VIETNAM IS MOVING FROM “KNOWING THE PRICE” TO “TRACING THE PRICE”

01/10/2026 Published by HealthBiz

Key Development Vietnam's Ministry of Health is moving toward a model that tracks medical devices not only at the final... Read more

Tags: #Vietnam

PATIENTS SWITCHING FROM INJECTIONS TO THE WEGOVY PILL LOST ANOTHER 4.1%: “ROUTE FLEXIBILITY” COULD BECOME A NEW GLP-1 COMPETITIVE ADVANTAGE

01/10/2026 Published by HealthBiz

Key Development Patients may not need to choose between pills and injections for their entire obesity-treatment journey. Early real-world evidence... Read more

Category: Uncategorized

Tags: #Global Trends

OZEMPIC SHOWS 6% LOWER ASSOCIATED MACE RISK THAN SWITCHING TO MOUNJARO: THE INCRETIN WAR IS MOVING FROM WEIGHT LOSS TO HARD OUTCOMES

30/09/2026 Published by HealthBiz

Key Development Novo Nordisk has added another cardiovascular data point to its competition with Eli Lilly — but this is... Read more

Category: Uncategorized

Tags: #Global Trends

LONG CHÂU–SANTEN EXPAND EYE-CARE PARTNERSHIP: PHARMACIES ARE EMERGING AS A NEW FRONT DOOR TO THE OPHTHALMOLOGY ECOSYSTEM

30/09/2026 Published by HealthBiz

Key Development Long Châu and Santen are moving beyond conventional product access toward a broader model built around eye-health education,... Read more

Category: Uncategorized

Tags: #Vietnam

LINKING PHARMA AND PHARMACEUTICAL CHEMICALS: VIETNAM NEEDS MORE THAN API PLANTS — IT NEEDS A BANKABLE VALUE CHAIN

30/09/2026 Published by HealthBiz

Key Development Vietnam's pharmaceutical-industry gap increasingly sits between two very different layers: a relatively broad finished-drug manufacturing base downstream and... Read more

Category: Uncategorized

Tags: #Vietnam

RETATRUTIDE DELIVERS NEARLY 21% WEIGHT LOSS IN DIABETES: LILLY IS PUSHING THE GLP-1 RACE FROM “WEIGHT LOSS” TOWARD FULL-SPECTRUM METABOLIC CONTROL

30/09/2026 Published by HealthBiz

Key Development Eli Lilly has released detailed Phase III TRIUMPH-2 results for retatrutide, its once-weekly GIP/GLP-1/glucagon triple receptor agonist, in... Read more

Category: Uncategorized

Tags: #Global Trends

ASTRAZENECA PUTS $2 BILLION BEHIND SUMMIT: THE PD-1×VEGF RACE IS SHIFTING FROM “WHO HAS THE BEST DRUG?” TO “WHO BUILDS THE BEST COMBINATION BACKBONE?”

30/09/2026 Published by HealthBiz

Key Development AstraZeneca is making a $2 billion strategic equity investment in Summit Therapeutics, giving it rights equivalent to approximately... Read more

Category: Uncategorized

Tags: #Global Trends

AMT-130 LOSES STATISTICAL SIGNIFICANCE AT FOUR YEARS: HUNTINGTON’S GENE THERAPY IS ENTERING A HARDER TEST – NOT SIMPLY “FAILING”

30/09/2026 Published by HealthBiz

Key Development uniQure’s latest 48-month readout has materially changed the investment and regulatory narrative around AMT-130, one of the most... Read more

Category: Uncategorized

Tags: #Global Trends